youtube_live
Q3 2026 earnings • in 1 day
See detailschevron_right
BCRX:NASDAQ
BioCryst Pharmaceuticals Inc
$8.24
arrow_downward
-2.66%(-0.23) 1D
$8.14
arrow_downward
-1.27% (-0.10)bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BCRX...
Open
$8.49
High
$8.52
Low
$8.22
Mkt. cap
2.11B
Avg. vol.
5.12M
Volume
0.00
52-wk high
$11.22
52-wk low
$6.23
EPS
-$1.50
Beta
0.55
Shares outstanding
255.54M
No. of employees
435
Open
$8.49
High
$8.52
Low
$8.22
Mkt. cap
2.11B
Avg. vol.
5.12M
Volume
0.00
52-wk high
$11.22
52-wk low
$6.23
EPS
-$1.50
Beta
0.55
Shares outstanding
255.54M
No. of employees
435
News stories
From web sources and news partners
Yahoo! Finance Canada
·
5 hours ago
AMN,HLF,BSBK,FXNC,IMRX,CRMT,MRBK,ORN,TISI,FRST,GRNT,VSTS,RVSB,GEF-B,SABR,TMCI,BCRX,SHEN,DCGO,NBBK,USCB | Stock Prices | Quote Comparison
Zacks
·
6 hours ago
Bioventus (BVS) Matches Q3 Earnings Estimates
Profile
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema and other rare diseases. BioCryst's antiviral drug peramivir was approved by the FDA in December 2014 and berotralstat was approved in December 2020. Wikipedia
About BioCryst Pharmaceuticals Inc
CEOJon P. Stonehouse
Employees435
Founded1986
HeadquartersDurham, North Carolina, United States
SectorBiotechnology
Websitebiocryst.com